日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Clinical validation of the PrecivityAD2 blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and Aβ42/40 ratio to identify presence of brain amyloid

PrecivityAD2血液检测的临床验证:一种基于质谱的检测方法,其算法结合了%p-tau217和Aβ42/40比值,用于识别脑淀粉样蛋白的存在。

Meyer, Matthew R; Kirmess, Kristopher M; Eastwood, Stephanie; Wente-Roth, Traci L; Irvin, Faith; Holubasch, Mary S; Venkatesh, Venky; Fogelman, Ilana; Monane, Mark; Hanna, Lucy; Rabinovici, Gil D; Siegel, Barry A; Whitmer, Rachel A; Apgar, Charles; Bateman, Randall J; Holtzman, David M; Irizarry, Michael; Verbel, David; Sachdev, Pallavi; Ito, Satoshi; Contois, John; Yarasheski, Kevin E; Braunstein, Joel B; Verghese, Philip B; West, Tim

Plasma Aβ42/Aβ40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease

血浆Aβ42/Aβ40和磷酸化tau217浓度比值可提高临床前阿尔茨海默病中淀粉样蛋白PET分类的准确性

Rissman, Robert A; Langford, Oliver; Raman, Rema; Donohue, Michael C; Abdel-Latif, Sara; Meyer, Matthew R; Wente-Roth, Traci; Kirmess, Kristopher M; Ngolab, Jennifer; Winston, Charisse N; Jimenez-Maggiora, Gustavo; Rafii, Michael S; Sachdev, Pallavi; West, Tim; Yarasheski, Kevin E; Braunstein, Joel B; Irizarry, Michael; Johnson, Keith A; Aisen, Paul S; Sperling, Reisa A

PrecivityAD2™ Blood Test: Analytical Validation of an LC-MS/MS Assay for Quantifying Plasma Phospho-tau217 and Non-Phospho-tau217 Peptide Concentrations That Are Used with Plasma Amyloid-β42/40 in a Multianalyte Assay with Algorithmic Analysis for Detecting Brain Amyloid Pathology

PrecivityAD2™ 血液检测:用于定量血浆中磷酸化 tau217 和非磷酸化 tau217 肽浓度的 LC-MS/MS 检测方法的分析验证,该方法与血浆淀粉样蛋白 β42/40 一起用于多分析物检测,并采用算法分析来检测脑淀粉样蛋白病理。

Eastwood, Stephanie M; Meyer, Matthew R; Kirmess, Kristopher M; Wente-Roth, Traci L; Irvin, Faith; Holubasch, Mary S; Verghese, Philip B; West, Tim; Braunstein, Joel B; Yarasheski, Kevin E; Contois, John H